Literature DB >> 8948345

Prognostic factors in the treatment of node-negative nonsmall cell lung carcinoma with radiotherapy alone.

P A Kupelian1, R Komaki, P Allen.   

Abstract

PURPOSE: For patients with early stage nonsmall cell lung carcinoma (NSCLC) but medically inoperable, aggressive radiation therapy might impact on survival. METHODS AND MATERIALS: Between 1980 and 1990, 71 patients treated at MDACC by radiation therapy alone for NSCLC because of medical contradindications for surgery were analyzed. All patients had histologic or cytologic confirmation of NSCLC. The median total radiation dose was 63.23 Gy with 79% of patients receiving doses exceeding 60 Gy. The radiographic response was documented at completion of radiation therapy and 6 months after completion of radiation therapy. The median follow-up time was 36 months, ranging from 14-61 months.
RESULTS: Overall survival rates at 3 and 5 years were 19 and 12%, respectively. The disease-specific survival (DSS) rates at 3 and 5 years were 44 and 32%, respectively. The DSS rates at 3 years by T-stage were: 49% for T1, 47% for T2, 26% for T3, and 32% for T4. The local control rates at 3 and 5 years were 66 and 56%, respectively. The local control rates at 3 years by T-stage were: 89% for T1, 61% for T2, 42% for T3, and 55% for T4. Univariately, the significant favorable prognostic factors for DSS were a KPS > or = 70, tumor size < or = 5 cm, no chest-wall invasion, and a radiation dose > or = 50 Gy. The significant favorable prognostic factors for local control were tumor size < or = 4 cm, no chest-wall invasion, a radiation dose > 60 Gy, and a complete response confirmed by chest x-ray at 6 months after radiotherapy (p = 0.04). Coverage of nodal drainage areas did not affect survival or local control. No lethal complications were seen, and documented symptomatic radiation pneumonitis occurred in only 7% of cases. Hence, the significant favorable prognostic factors for DSS were a KPS of > or = 70, tumor size < or = 5 cm, no chest-wall invasion, and a radiation dose > or = 50 Gy. The significant favorable prognostic factors for local control were tumor size of < or = 4 cm, no chest-wall invasion, a radiation dose > 60 Gy, and a complete response confirmed by chest x-ray at 6 months after radiotherapy. Multivariate analysis showed that the most important prognostic factor for DSS was KPS, and the most important prognostic factor for local control was radiation dose.
CONCLUSIONS: Patients with a KPS of > or = 70, a tumor size < 5 cm, and no chest-wall invasion would benefit most from treatment with radiation alone to doses exceeding 60 Gy. This patient group represents the best sample for studying the benefit of conformal radiotherapy.

Entities:  

Mesh:

Year:  1996        PMID: 8948345     DOI: 10.1016/s0360-3016(96)00364-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

Review 1.  The role of percutaneous image-guided ablation for lung tumors.

Authors:  Elena N Petre; Stephen B Solomon; Constantinos T Sofocleous
Journal:  Radiol Med       Date:  2014-07-01       Impact factor: 3.469

Review 2.  Are three doses of stereotactic ablative radiotherapy (SABR) more effective than 30 doses of conventional radiotherapy?

Authors:  Anna O Simeonova; Katharina Fleckenstein; Hansjörg Wertz; Anian Frauenfeld; Judit Boda-Heggemann; Frank Lohr; Frederik Wenz
Journal:  Transl Lung Cancer Res       Date:  2012-03

Review 3.  Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review.

Authors:  N P Rowell; C J Williams
Journal:  Thorax       Date:  2001-08       Impact factor: 9.139

4.  Datamining approaches for modeling tumor control probability.

Authors:  Issam El Naqa; Joseph O Deasy; Yi Mu; Ellen Huang; Andrew J Hope; Patricia E Lindsay; Aditya Apte; James Alaly; Jeffrey D Bradley
Journal:  Acta Oncol       Date:  2010-03-02       Impact factor: 4.089

Review 5.  [Stereotactic irradiation of lung tumors].

Authors:  H Hof; K Herfarth; J Debus
Journal:  Radiologe       Date:  2004-05       Impact factor: 0.635

6.  The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer.

Authors:  Li Wang; Candace R Correa; Lujun Zhao; James Hayman; Gregory P Kalemkerian; Susan Lyons; Kemp Cease; Dean Brenner; Feng-Ming Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-17       Impact factor: 7.038

7.  Is there a selection bias in radiotherapy dose-escalation protocols?

Authors:  Elisabeth Weiss; Viswanathan Ramakrishnan; Paul J Keall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-07       Impact factor: 7.038

8.  Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer.

Authors:  Thomas E Stinchcombe; Lydia Hodgson; James E Herndon; Michael J Kelley; M Giulia Cicchetti; Nithya Ramnath; Harvey B Niell; James N Atkins; Wallace Akerley; Mark R Green; Everett E Vokes
Journal:  J Thorac Oncol       Date:  2009-09       Impact factor: 15.609

9.  Image-guided radiofrequency ablation of lung neoplasm in 100 consecutive patients by a thoracic surgical service.

Authors:  Arjun Pennathur; Ghulam Abbas; William E Gooding; Matthew J Schuchert; Sebastien Gilbert; Neil A Christie; Rodney J Landreneau; James D Luketich
Journal:  Ann Thorac Surg       Date:  2009-11       Impact factor: 4.330

10.  Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC.

Authors:  Daniel Morgensztern; Lingling Du; Saiama N Waqar; Aalok Patel; Pamela Samson; Siddhartha Devarakonda; Feng Gao; Cliff G Robinson; Jeffrey Bradley; Maria Baggstrom; Ashiq Masood; Ramaswamy Govindan; Varun Puri
Journal:  J Thorac Oncol       Date:  2016-06-08       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.